Mark James Litton Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark James Litton.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark James Litton. Mark James Litton is Chief Business Officer in ALDER BIOPHARMACEUTICALS INC ($ALDR) and Chief Operating Officer in Athira Pharma, Inc. ($ATHA) and See Remarks in ALPINE IMMUNE SCIENCES, INC. ($ALPN).
Latest Insider Trading Transactions of Mark James Litton
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALDR, ALPN, ATHA
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 22 2021 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Option Exercise | A | 21.15 | 85,000 | 1,797,750 | 85,000 | |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Option Exercise | C | 0.00 | 6,563 | 0 | 0 | |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Option Exercise | C | 0.00 | 6,563 | 0 | 0 | |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Option Exercise | C | 0.00 | 6,563 | 0 | 0 | |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Option Exercise | C | 0.00 | 13,126 | 0 | 0 | |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Buy | C | 0.00 | 6,563 | 0 | 6,563 | 0 to 6.6 K |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Buy | C | 0.00 | 6,563 | 0 | 6,563 | 0 to 6.6 K |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Buy | C | 0.00 | 6,563 | 0 | 6,563 | 0 to 6.6 K |
| Sep 22 2020 | ATHA | Athira Pharma, Inc ... | Litton Mark James | Chief Operating Off ... | Buy | C | 0.00 | 13,126 | 0 | 63,566 | 50.4 K to 63.6 K (+26.02 %) |
| Feb 08 2019 | ALPN | ALPINE IMMUNE SCIE ... | Litton Mark James | See Remarks | Option Exercise | A | 6.51 | 75,000 | 488,250 | 75,000 | |
| Feb 08 2019 | ALPN | ALPINE IMMUNE SCIE ... | Litton Mark James | See Remarks | Option Exercise | A | 6.81 | 25,000 | 170,250 | 25,000 | |
| Aug 08 2018 | ALPN | ALPINE IMMUNE SCIE ... | Litton Mark James | See Remarks | Option Exercise | A | 6.81 | 150,000 | 1,021,500 | 150,000 | |
| Jun 05 2018 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 0.99 | 22,727 | 22,500 | 0 | |
| Jun 05 2018 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 18.24 | 4,474 | 81,587 | 102,189 | 106.7 K to 102.2 K (-4.19 %) |
| Jun 05 2018 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 17.74 | 18,253 | 323,825 | 106,663 | 124.9 K to 106.7 K (-14.61 %) |
| Jun 05 2018 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 0.99 | 22,727 | 22,500 | 124,916 | 102.2 K to 124.9 K (+22.24 %) |
| Feb 21 2018 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | A | 13.55 | 75,000 | 1,016,250 | 75,000 | |
| Nov 15 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.65 | 16,519 | 27,256 | 0 | |
| Nov 15 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 10.80 | 16,519 | 178,486 | 99,932 | 116.5 K to 99.9 K (-14.19 %) |
| Nov 15 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 1.65 | 16,519 | 27,256 | 116,451 | 99.9 K to 116.5 K (+16.53 %) |
| Oct 18 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.65 | 16,520 | 27,258 | 16,519 | |
| Oct 18 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 12.33 | 16,520 | 203,703 | 99,932 | 116.5 K to 99.9 K (-14.19 %) |
| Oct 18 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 1.65 | 16,520 | 27,258 | 116,452 | 99.9 K to 116.5 K (+16.53 %) |
| Jan 31 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | A | 20.40 | 60,000 | 1,224,000 | 60,000 | |
| Jan 20 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.65 | 1,498 | 2,472 | 33,039 | |
| Jan 20 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 23.10 | 1,498 | 34,599 | 99,932 | 101.4 K to 99.9 K (-1.48 %) |
| Jan 20 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 1.65 | 1,498 | 2,472 | 101,430 | 99.9 K to 101.4 K (+1.50 %) |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.65 | 500 | 825 | 34,537 | |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.65 | 1,326 | 2,188 | 35,037 | |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.27 | 5,474 | 6,925 | 0 | |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.27 | 2,216 | 2,803 | 5,474 | |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 23.00 | 500 | 11,500 | 99,932 | 100.4 K to 99.9 K (-0.50 %) |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | M | 1.65 | 500 | 825 | 100,432 | 100.9 K to 100.4 K (-0.50 %) |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 23.02 | 6,800 | 156,520 | 99,932 | 106.7 K to 99.9 K (-6.37 %) |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 1.65 | 1,326 | 2,188 | 106,732 | 105.4 K to 106.7 K (+1.26 %) |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 1.27 | 5,474 | 6,925 | 105,406 | 99.9 K to 105.4 K (+5.48 %) |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 23.00 | 2,216 | 50,972 | 99,932 | 102.1 K to 99.9 K (-2.17 %) |
| Jan 09 2017 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 1.27 | 2,216 | 2,803 | 102,148 | 99.9 K to 102.1 K (+2.22 %) |
| Oct 19 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 27.50 | 2,000 | 55,000 | 26,000 | 28 K to 26 K (-7.14 %) |
| Oct 19 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 27.50 | 2,000 | 55,005 | 26,000 | 28 K to 26 K (-7.14 %) |
| Oct 19 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 27.50 | 2,000 | 54,993 | 26,000 | 28 K to 26 K (-7.14 %) |
| Jul 14 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 0.39 | 25,000 | 9,625 | 0 | |
| Jul 14 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 0.39 | 25,000 | 9,625 | 99,567 | 74.6 K to 99.6 K (+33.53 %) |
| Jun 01 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 0.39 | 19,720 | 7,592 | 25,000 | |
| Jun 01 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 0.39 | 5,280 | 2,033 | 44,720 | |
| Jun 01 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 30.05 | 19,720 | 592,566 | 74,567 | 94.3 K to 74.6 K (-20.91 %) |
| Jun 01 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 0.39 | 19,720 | 7,592 | 94,287 | 74.6 K to 94.3 K (+26.45 %) |
| Jun 01 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 30.06 | 5,280 | 158,693 | 74,567 | 79.8 K to 74.6 K (-6.61 %) |
| Jun 01 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 0.39 | 5,280 | 2,033 | 79,847 | 74.6 K to 79.8 K (+7.08 %) |
| Feb 02 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | A | 24.18 | 50,000 | 1,209,000 | 50,000 | |
| Jan 06 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 0.39 | 25,000 | 9,625 | 50,000 | |
| Jan 06 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 31.86 | 7,709 | 245,573 | 73,718 | 81.4 K to 73.7 K (-9.47 %) |
| Jan 06 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 31.19 | 17,291 | 539,379 | 81,427 | 98.7 K to 81.4 K (-17.52 %) |
| Jan 06 2016 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 0.39 | 25,000 | 9,625 | 98,718 | 73.7 K to 98.7 K (+33.91 %) |
| Oct 05 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 32.81 | 560 | 18,373 | 72,919 | 73.5 K to 72.9 K (-0.76 %) |
| Oct 05 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 32.22 | 6,940 | 223,630 | 73,479 | 80.4 K to 73.5 K (-8.63 %) |
| Sep 28 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 1.27 | 12,764 | 16,146 | 7,690 | |
| Sep 28 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 1.27 | 12,764 | 16,146 | 80,419 | 67.7 K to 80.4 K (+18.87 %) |
| Jul 06 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 51.10 | 7,500 | 383,219 | 67,655 | 75.2 K to 67.7 K (-9.98 %) |
| Jun 08 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | M | 0.39 | 25,000 | 9,625 | 75,000 | |
| Jun 08 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 44.27 | 25,000 | 1,106,853 | 75,155 | 100.2 K to 75.2 K (-24.96 %) |
| Jun 08 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Buy | M | 0.39 | 25,000 | 9,625 | 100,155 | 75.2 K to 100.2 K (+33.26 %) |
| Apr 03 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 27.41 | 7,500 | 205,553 | 74,359 | 81.9 K to 74.4 K (-9.16 %) |
| Jan 28 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | A | 28.23 | 35,000 | 988,050 | 35,000 | |
| Jan 28 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 28.52 | 2,300 | 65,602 | 81,859 | 84.2 K to 81.9 K (-2.73 %) |
| Jan 28 2015 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 28.03 | 5,200 | 145,732 | 84,159 | 89.4 K to 84.2 K (-5.82 %) |
| Nov 24 2014 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Sell | S | 15.63 | 30,000 | 469,011 | 88,484 | 118.5 K to 88.5 K (-25.32 %) |
| Jul 10 2014 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | A | 16.90 | 25,000 | 422,500 | 25,000 | |
| May 09 2014 | ALDR | ALDER BIOPHARMACEU ... | Litton Mark James | Chief Business Offi ... | Option Exercise | A | 10.00 | 9,090 | 90,900 | 9,090 |
Page: 1